JBIO Q3 2024 Earnings — Jade Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

JBIOJade Biosciences, Inc.

$491M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$15M

Net Income

-$16M

EPS (Diluted)

$-5.16

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

$37M

Free Cash Flow

$37M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$91M

Total Liabilities

$10M

Stockholders' Equity

$80M

Cash & Equivalents

$31M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$25,000	+100.0%
Operating Income	-$15M	-$21M	+30.0%
Net Income	-$16M	-$20M	+16.8%